Changes in Fluoroquinolone-Resistant Streptococcus pneumonia after 7-Valent Conjugate Vaccination, Spain
Adela G. de la Campa , Carmen Ardanuy, Luz Balsalobre, Emilio Pérez-Trallero, Jose M. Marimón, Asunción Fenoll, and Josefina Liñares
Author affiliations: Instituto de Salud Carlos III, Madrid, Spain (A.G. de la Campa, L. Balsalobre, A. Fenoll); Ciber Enfermedades Respiratorias, Mallorca, Spain (A.G. de la Campa, C. Ardanuy, L. Balsalobre, E. Pérez-Trallero, J. M. Marimón, J. Liñares); Hospital Universitary de Bellvitge, Barcelona, Spain (C. Ardanuy, J. Liñares); Hospital Donostia, San Sebastian, Spain (E. Pérez-Trallero, J.M. Marimón)
Figure. Serotype (A) and genotype (B) distributions of ciprofloxacin-resistant pneumococci isolated in Spain, 2002 and 2006. A total of 75 isolates from 2002 (black columns) and 98 from 2006 (white columns) were compared. Asterisks indicate significant differences (p<0.05) between the 2 years. PCV7, 7-valent conjugate pneumococcal vaccine. Baseline numbers in B indicate various genotypes. 1, Spain6B-ST90; 2, Spain9V-ST156; 3, Spain14-ST17; 4, Netherlands18C-ST113; 5, ST8819F; 6, Spain23F-ST81; 7, Netherlands3-ST180; 8, ST2603; 9, ST9710A; 10, ST6211A; 11, Sweden15A-ST63; 12, ST57016; 13, TS43322; 14, ST71733; 15, other.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.